Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Oncolytics Biotech ( (ONCY) ).
On November 4, 2025, Oncolytics Biotech announced the formation of a Gastrointestinal Tumor Scientific Advisory Board (SAB) to guide the clinical and regulatory strategy for pelareorep as a treatment for gastrointestinal cancers. The SAB, consisting of leading oncology experts, will play a crucial role in shaping the company’s GI oncology development strategy, including designing registration-enabling studies and exploring pathways for accelerated approval in select tumor types. This initiative is expected to strengthen Oncolytics’ position in the industry and potentially transform the treatment landscape for patients with GI tumors.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for the treatment of metastatic pancreatic and breast cancers, as well as other gastrointestinal tumors. Oncolytics is actively seeking strategic partnerships to accelerate development and maximize commercial impact.
Average Trading Volume: 1,017,744
Technical Sentiment Signal: Hold
Current Market Cap: $110.4M
Learn more about ONCY stock on TipRanks’ Stock Analysis page.